Patents Examined by Sabiha Qazi
-
Patent number: 7985209Abstract: A wound or surgical dressing is disclosed. The wound or surgical dressing is configured to cover or surround a wound, a surgical incision, or any type of skin irritation. In accordance with the present disclosure, the wound or surgical dressing is treated with a bacteriostatic composition that is capable of binding and trapping negatively charged matter, such as bacteria, pathogens, and the like. The bacteriostatic composition comprises a cationic polymer, a cationic oligomer, or particles coated with a cationic material. The bacteriostatic composition is bonded to the wound or surgical dressing in a manner such that the bacteriostatic composition is not substantially transferred to a patient being treated.Type: GrantFiled: December 15, 2005Date of Patent: July 26, 2011Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Julie M. Villanueva, Curtis Neil Sayre, Lei Huang, Kevin Peter McGrath, Ning Wei
-
Patent number: 7985744Abstract: The object of the present invention is to provide vitamin D derivatives that have excellent physiological activities as medicines, particularly as therapeutic agents for skin diseases such as psoriasis, and that have a reduced hypercalcemic effect. The present invention provides a vitamin D derivative of Formula (1): wherein X represents an oxygen atom or a sulfur atom; m represents a number of 1 to 3; R1 and R2 each represent a hydrogen atom or an alkyl group; R4 and R5 each represent a hydrogen atom or a hydroxyl group, etc.; R3 represents —YR8, etc.; R6 represents a hydrogen atom, etc.; R7 represents a hydrogen atom, etc.Type: GrantFiled: June 14, 2001Date of Patent: July 26, 2011Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Kazumi Morikawa, Masayuki Ohmori, Kazuki Shimizu, Akira Kawase, Takashi Emura
-
Patent number: 7964639Abstract: A method of minimizing or reducing the toxicity of a retinoid having a free carboxyl group and the resulting modified retinoids are described. The method comprises the step of esterifying the carboxyl group of the retinoid with a highly sterically hindered compound, which is preferably a secondary or tertiary alcohol. The resulting retinoid esters are rendered much less toxic than the starting or parent retinoid. This process provides a retinoid ester analog of reduced toxicity so that it may be administered orally with minimal side effects and with a much greater therapeutic window. The modified retinoid compounds are useful in the treatment and prophylaxis of all diseases and disorders where retinoid compounds have been shown effective.Type: GrantFiled: January 16, 2004Date of Patent: June 21, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Margaret Clagett-Dame, Sumithra Gowlugari
-
Patent number: 7960368Abstract: Described herein are bismethylene-17? carbolactone derivatives having progestational and/or antimineralocorticoid and/or aldosterone antagonistic activity. Also described herein are methods of preparing and using these novel compounds.Type: GrantFiled: March 4, 2009Date of Patent: June 14, 2011Assignee: Everstra, Inc.Inventors: Klaus Nickisch, Pemmaranu N. Rao, James W. Cessac, Anne Marie Simmons
-
Patent number: 7951965Abstract: The present invention discloses a phenanthrene derivative having the following structure: wherein Ar1 and Ar2 independently are phenyl, nathphyl, heterocyclic group, polycyclic aromatic or polycyclic heterocyclic group with at least one conjugated substituent. The conjugated substituent can be an electron withdrawing group or electron donating group. The phenanthrene derivatives have semiconductor properties of electron transfer, electroluminescence (EL), and photoluminescence (PL). Intermolecular stacking can be avoided and electron-luminescent emission stability is enhanced when the derivatives are applied as a light-emitting material in organic EL devices due to the presence of the two stereo cyclopentane rings, such as a host compound or a dopant emitting blue light.Type: GrantFiled: February 4, 2005Date of Patent: May 31, 2011Assignee: Industrial Technology Research InstituteInventors: Chi Shen Tuan, Zong-Wei Tsai, Ching-Ian Chao, Shyue-Ming Jang, Chia-Kuo Yen
-
Patent number: 7951752Abstract: A compound of formula (I): F1 Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by groups R4, R5 and R6; R1 is hydrogen or halo; R2 is hydrogen or halo; R3 is optionally substituted C2-12 alkyl, optionally substituted C2-12 alkenyl, optionally substituted C2-12 alkynyl, optionally substituted C3-12 cycloalkyl, optionally substituted phenyl or optionally substituted heterocyclyl; and R4, R5 and R6 are, independently, selected from hydrogen, halo, cyano, nitro, C1-4 haloalkyl, C1-4 alkoxyl (C(1-4) alkoxyl (C1-4) alkyl and C1-4 haloalkoxy (C1-4) alkyl, provided that at least one of R4, R5 and R6 is not hydrogen. The compounds of formula (I) have plant-protective properties and are suitable for protecting plants against infestations by phytopathogenic microorganisms.Type: GrantFiled: February 21, 2003Date of Patent: May 31, 2011Assignee: Syngenta Crop Protection, Inc.Inventors: Josef Ehrenfreund, Hans Tobler, Harald Walter
-
Patent number: 7947666Abstract: This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-1?,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.Type: GrantFiled: December 24, 2008Date of Patent: May 24, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum, Grazia Chiellini, Pawel Grzywacz
-
Patent number: 7947679Abstract: The naphthyridine derivatives of formula (I) a and method of combating or controlling phytopathogenic fungi which comprises applying the compounds of formula (I) to a plant, to a seed of a plant and to the locus of the plant.Type: GrantFiled: December 3, 2003Date of Patent: May 24, 2011Assignee: Syngenta Crop Protection, Inc.Inventors: Patrick Jelf Crowley, Markus Dobler, Urs Mueller, John Williams
-
Patent number: 7947667Abstract: A process for preparing an intermediate compound of formula (II) where X is as defined in the specification, R1 is haloalkyl, alkyl, alkenyl, cycloalkyl, carboxyalkyl, alkoxycarbonylalkyl, aryl or arylalkyl; R2, R3, R4 and R5 are organic groups as defined in the specification, which process comprises aromatisation of a compound of formula (III) where R1, R2, R3, n, X and R5 are as defined in relation to formula (II) and R4? is a group R4 or a precursor group thereof, and thereafter if necessary or desired, carrying out one or more of the following steps: (i) removing any hydroxy-protecting groups R; (ii) converting a precursor group R4? to a group R4, or where R4? is a group R4, converting it to a different such group. Compounds obtained are useful intermediates for example in the preparation of fulvestrant. Novel intermediates are also claimed.Type: GrantFiled: October 9, 2001Date of Patent: May 24, 2011Assignee: AstraZeneca ABInventors: Robert Stevenson, Fraser Witton Kerr, Anthony Raymond Lane, Eve Joanne Brazier, Phillip John Hogan, David Dermot Patrick Laffan
-
Patent number: 7943601Abstract: This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1?-hydroxy-19,24,25,26,27-pentanor-vitamin D3, and pharmaceutical uses therefore. This compound exhibits activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.Type: GrantFiled: December 24, 2008Date of Patent: May 17, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Margaret Clagett-Dame, Lori A. Plum, Agnieszka Glebocka, Rafal R. Sicinski
-
Patent number: 7939513Abstract: In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds. wherein R1 is selected from optionally substituted alkyl.Type: GrantFiled: September 8, 2008Date of Patent: May 10, 2011Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Mohamed Takhi, Natesan Selvakumar, Sreenivas Kandepu, Gavara Govinda Rajulu, Javed Iqbal
-
Patent number: 7915199Abstract: A selective herbicidal composition for controlling grasses and weeds in crops of cultivated plants, comprising a) a herbicidally effective amount of a compound of formula I wherein the substituents are defined as given in claim 1; b) a herbicidally synergistic amount of at least one herbicide selected from the classes of phenoxy-phenoxypropionic acids, hydroxylamines, sulfonylureas, imidazolinones, pyrimidines, triazines, ureas, PPO, chloroacetanilides, phenoxyacetic acids, triazinones, dinitroanilines, azinones, carbamates, oxyacetamides, thiolcarbamates, azole-ureas, benzoic acids, anilides, nitriles, triones and sulfonamides, as well as from the herbicides amitrol, benfuresate, bentazone, cinmethylin, clomazone, chlopyralid, difenzoquat, dithiopyr, ethofumesate, flurochloridone, indanofane, isoxaben, oxaziclomefone, pyridate, pyridafol, quinchlorac, quinmerac, tridiphane and flamprop; and optionally c) to antagonise the herbicide, an antidotally effective amount of a safener selected from cloType: GrantFiled: September 5, 2000Date of Patent: March 29, 2011Assignee: Syngenta Crop Protection, Inc.Inventors: Jutta Glock, Adrian Alberto Friedmann, Derek Cornes
-
Patent number: 7915241Abstract: Disclosed is a process for the preparation of 24-alkyl analogs of cholecalcyferol of Formula 1 having a (5E) or (5Z) configuration, wherein X represents a hydrogen atom, a hydroxy group or an OR1 group, where R1, R2 and R3 may be the same or different and represent groups suitable for hydroxyl protection, and R4 is a C1-6 alkyl chain or a C1-6 cykloalkyl group, optionally substituted with C1-3 alkyl groups, especially for calcipotriol. The invention also provides new intermediates and non-racemic compounds being valuable synthones for the synthesis of pharmacologically active substances.Type: GrantFiled: October 8, 2004Date of Patent: March 29, 2011Assignee: Instytut FarmaceutycznyInventors: Andrzej Kutner, Jacek Martynow, Michal Chodynski, Wieslaw Szelejewski, Hanna Fitek, Malgorzata Krupa
-
Patent number: 7915242Abstract: Various compounds such as those having the formula I and XIV where the variables have the values described herein antagonize the vitamin D receptor and are useful in treating conditions such as asthma and in preparing medicaments for use in antagonizing the vitamin D receptor or treating conditions such as asthmaType: GrantFiled: February 16, 2005Date of Patent: March 29, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Rafal Barycki, Moisés A. Rivera-Bermúdez, Lori A. Plum, Margaret Clagett-Dame
-
Patent number: 7902231Abstract: This invention provides compounds of Formula 1, their N-oxides and agriculturally suitable salts wherein R1, R2, R3, R4a, R4b and R5 are as defined in the disclosure. Also disclosed are methods for controlling invertebrate pests comprising contacting the invertebrate pests or their environment with a biologically effective amount of a compound of Formula 1 or a composition comprising a compound of Formula 1.Type: GrantFiled: April 18, 2007Date of Patent: March 8, 2011Assignee: E.I. du Pont de Nemours and CompanyInventors: George Philip Lahm, Thomas Paul Selby, Thomas Martin Stevenson
-
Patent number: 7893043Abstract: This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1?, 25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has significant calcemic activity in vivo having about the same bone calcium mobilization activity and intestinal calcium transport activity as the native hormone 1?,25-dihydroxyvitamin D3, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.Type: GrantFiled: July 10, 2008Date of Patent: February 22, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Bulli Padmaja Tadi, Lori A. Plum, Margaret Ciagett-Dame
-
Patent number: 7888339Abstract: This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1?,25-dihydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows lower activity in vivo on bone calcium mobilization and similar in vivo intestinal calcium transport activity compared to the native hormone 1?,25-dihydroxyvitamin D3, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.Type: GrantFiled: July 10, 2008Date of Patent: February 15, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Bulli Padmaja Tadi, Lori A. Plum, Margaret Clagett-Dame
-
Patent number: 7888338Abstract: The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating diseases, illnesses, and the like with said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes.Type: GrantFiled: December 6, 2005Date of Patent: February 15, 2011Assignees: K.U. Leuven Research & Development, Universiteit GentInventors: Roger Bouillon, Pierre De Clercq, Wim Schepens, Maurits Vandewalle, Annemieke Verstuyf
-
Patent number: 7879829Abstract: 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1?-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperparathyroidism, psoriasis, or other skin diseases.Type: GrantFiled: July 10, 2008Date of Patent: February 1, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Agnieszka Glebocka, Katarzyna Sokolowska, Rafal R. Sicinski, Lori A. Plum, Margaret Clagett-Dame
-
Patent number: 7875606Abstract: The present invention aims at providing an isoxazoline derivative and a pharmaceutically acceptable salt thereof, both having an excellent herbicidal effect and an excellent selectivity between crop and weed. The isoxazoline derivative of the present invention is represented by the following general formula: wherein R1 is a haloalkyl group; R2 is a hydrogen atom, an alkyl group, or the like; R3, R4, R5 and R6 are each a hydrogen atom, or the like; Y is a pyrrolyl group, a pyrazolyl group, an isothiazolyl group, an oxazolyl group, an imidazolyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, a triazinyl group, a triazolyl group, an oxadiazolyl group, or the like; and n is an integer of 0 to 2.Type: GrantFiled: June 20, 2002Date of Patent: January 25, 2011Assignees: Ihara Chemical Industry Co., Ltd., Kumiai Chemical Industry Co., Ltd.Inventors: Masao Nakatani, Minoru Ito, Kyoko Kimijima, Masahiro Miyazaki, Makoto Fujinami, Ryohei Ueno, Satoru Takahashi